|
First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. |
|
|
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; SERVIER |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Servier |
Research Funding - Amgen; Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Eisai; Merck; MSD; SERVIER |
Speakers' Bureau - Amgen; Bayer; Merck |
Travel, Accommodations, Expenses - Merck; SERVIER |
|
|
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Roche; SERVIER |
Travel, Accommodations, Expenses - Bayer; Roche; SERVIER |
|
|
Consulting or Advisory Role - Astellas Pharma; Tesaro |
Research Funding - Astellas Pharma; QED Therapeutics |
|
|
Patents, Royalties, Other Intellectual Property - International Patent nr. PCT/EP2012/065661 |
|
|
Consulting or Advisory Role - Amgen; Bayer; Sanofi |
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi |
Research Funding - Amgen (Inst); Bayer (Inst); Merck Serono (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche |